BRPI0511941A - uso de (s, s)-reboxetina ou reboxetina racêmica - Google Patents

uso de (s, s)-reboxetina ou reboxetina racêmica

Info

Publication number
BRPI0511941A
BRPI0511941A BRPI0511941-3A BRPI0511941A BRPI0511941A BR PI0511941 A BRPI0511941 A BR PI0511941A BR PI0511941 A BRPI0511941 A BR PI0511941A BR PI0511941 A BRPI0511941 A BR PI0511941A
Authority
BR
Brazil
Prior art keywords
pain
reboxetine
racemic
medicament
manufacture
Prior art date
Application number
BRPI0511941-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernadette Hughes
Ian Mckenzie
Malcolm John Stoker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0511941A publication Critical patent/BRPI0511941A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0511941-3A 2004-06-09 2005-05-27 uso de (s, s)-reboxetina ou reboxetina racêmica BRPI0511941A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0511941A true BRPI0511941A (pt) 2008-01-22

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511941-3A BRPI0511941A (pt) 2004-06-09 2005-05-27 uso de (s, s)-reboxetina ou reboxetina racêmica

Country Status (12)

Country Link
US (1) US20080261984A1 (enExample)
EP (1) EP1763354A2 (enExample)
JP (1) JP2008501778A (enExample)
KR (1) KR20070029740A (enExample)
AU (1) AU2005256944A1 (enExample)
BR (1) BRPI0511941A (enExample)
CA (1) CA2567365A1 (enExample)
IL (1) IL178827A0 (enExample)
MX (1) MXPA06014389A (enExample)
NO (1) NO20064642L (enExample)
RU (1) RU2006143659A (enExample)
WO (1) WO2006000903A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20210177881A1 (en) * 2018-04-17 2021-06-17 Shanghai Tonglian Pharmaceutical Co., Ltd. Medicament for preventing and/or treating pain and/or fever, composite product and use thereof
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
US20190381056A1 (en) * 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20240119194A (ko) * 2018-10-15 2024-08-06 액섬 테라퓨틱스, 인크. 기면증 치료를 위한 레복세틴의 용도
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US20240415842A1 (en) * 2019-12-03 2024-12-19 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
DE60026704T2 (de) * 1999-07-01 2006-10-19 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetine zur Behandlung chronischer Schmerzen
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0413726A (pt) * 2003-09-09 2006-11-07 Pfizer Prod Inc combinação de inibidores da recaptação de serotonina e inibidores da recaptação de norepinefrina
RU2320369C2 (ru) * 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина

Also Published As

Publication number Publication date
IL178827A0 (en) 2007-03-08
AU2005256944A1 (en) 2006-01-05
CA2567365A1 (en) 2006-01-05
KR20070029740A (ko) 2007-03-14
JP2008501778A (ja) 2008-01-24
NO20064642L (no) 2006-11-13
EP1763354A2 (en) 2007-03-21
RU2006143659A (ru) 2008-06-20
MXPA06014389A (es) 2007-02-19
WO2006000903A2 (en) 2006-01-05
WO2006000903A3 (en) 2006-06-08
US20080261984A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
BRPI0511941A (pt) uso de (s, s)-reboxetina ou reboxetina racêmica
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200970224A1 (ru) Лечение заболеваний хряща
MX2007004051A (es) Pi3-quinasas.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
EA200802204A1 (ru) Применение ингибиторов dpp iv
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
SG135192A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
BRPI0511300A (pt) opióides para o tratamento da sìndrome das pernas inquietas
JP2008501778A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.